Diamyd Medical’s associated company Cellaviva launches service for private family saving of stem cells


Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today
that the Company’s associated company Cellaviva AB on September 1 launches its
service in which expecting parents in Sweden can save stem cells from their
newborn child. Stem cells from the baby’s umbilical cord are saved and stored
for at least 20 years in Cellaviva’s biobank. See today’s press release from
Cellaviva, http://www.mynewsdesk.com/se/

cellaviva-ab.
Diamyd Medical is with its share holding of approximately 39% one of the
principal owners of Cellaviva.The reason for Diamyd Medical to be one of the
major owners of Cellaviva is, as previously announced, based on Diamyd Medical’s
vision that in the future, it should be possible to differentiate insulin
-producing cell from stem cells. These could then help the donor, or close
relatives who have developed type 1 diabetes.

About Cellaviva
Cellaviva is the first private umbilical cord blood bank in Sweden to offer
families the opportunity to save stem cells from their newborn children. The
operations are under the supervision of the Health and Social Care Inspectorate
(IVO). Website: www.cellaviva.se.

About Diamyd Medical
Diamyd Medical is dedicated to working toward a cure for type 1 diabetes and
LADA. The Company’s projects include development of combination regimens with
the GAD-based diabetes vaccine Diamyd® for arresting the destruction of insulin
-producing beta cells. Diamyd® is considered to be the world’s furthest
developed Antigen Based Therapy (ABT) for treating the disease. The Company
exclusively licenses UCLA-rights to GAD65, the active ingredient in the vaccine,
for which the last patent expires in 2032. Additionally, the Company exclusively
licenses UCLA patents for using GABA for the treatment of diabetes and other
inflammation-related conditions.

Diamyd Medical is one of the major shareholders in the stem cell company
Cellaviva AB, which offers private family saving of stem cells in umbilical cord
blood. Stem cells can be expected to be used in Personalized Regenerative
Medicine (PRM), for example, to restore beta cell mass in diabetes patients
where autoimmunity has been arrested.

Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.

Attachments

08247523.pdf